Company intelligence / Profile preview

Phenex Pharmaceuticals AG

Ludwigshafen, Germanylife-sciences-europe.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Phenex has developed several drug candidates targeting nuclear receptors, with their most advanced program (FXR agonist) being acquired by Gilead and advancing to Phase 2 clinical trials for NASH, PBC, and PSC.

Therapeutic areas: GastroenterologyOncologyDermatologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Partnerships

Gilead Sciences

Beyond the preview

Go deeper on Phenex Pharmaceuticals AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phenex Pharmaceuticals AG.

Explore the full profile